John Treanor, M.D.
Professor of Medicine and Professor of Microbiology and Immunology
Department of Medicine
Division of Infectious Diseases
Human immune responses to influenza virus, and clinical vaccine trials
John Treanor, M.D. is the Director of the New York Center of Excellence and leads the clinical core. He received his medical degree in 1979 from the University of Rochester and fellowship in Infectious Diseases at the University of Rochester. Dr. Treanor is currently Professor of Medicine, Microbiology, and Immunology, and Chief of the Infectious Diseases Division at the University of Rochester Medical Center. Dr. Treanor has a long-standing interest in clinical research on influenza and vaccine development, and has been particularly involved in the clinical development of potential live vaccines for pandemic influenza. Dr. Treanor directs the activities of the clinical core, including designing studies to assess the immune response to infection and vaccination, and assessing population immunity to pandemic threat viruses.
David Topham, Ph.D.
Associate Professor of Microbiology and Immunology
David H Smith Center for Vaccine Biology and Immunology
T cell responses to influenza virus infection
The specter of a pandemic caused by avian influenza virus highlights the need to identify possible mechanisms of immune protection from emerging strains of the flu virus. We cannot accurately predict which influenza will emerge as the next pandemic, making it difficult to select and manufacture sufficient conventional vaccine to elicit protective homotypic antibodies. Protective T cell mediated heterosubtypic immunity to influenza is an established paradigm in animal models, but is not well documented in humans. Though it is likely that heterosubtypic immunity to influenza exists in humans, there is little evidence of its specificity, and the reasons why it may or may not be protective are unclear. Our lab has shown that optimal CD8 T cell mediated heterosubtypic immunity is provided when T cells are retained in the lung tissue and airways via their interaction with collagen via the VLA-1 collagen receptor (Ray et al., 2004). One hypothesis is that heterosubtypic immunity to influenza fails in humans because of insufficient memory in the lung tissue. Having these T cells in place would not prevent infection, but could limit the duration and magnitude of viral replication. This could be the difference between life and death when encountering an emerging pandemic strain of influenza. Conventional influenza subunit vaccination is designed to generate antibodies, and does not strongly stimulate tissue-memory. Future strategies for influenza vaccine design should target both antibodies and cross-reactive lymphoid and tissue memory T cells. Our goals are to better understand potentially heterosubtypic immune responses to influenza and begin to develop the means to evaluate and, in the future, promote optimal vaccination strategies. To accomplish these goals, the Topham lab has established assays for detailed analysis of cell-mediated immunity (CMI) against influenza in humans, and has developed improved animal models for studying CD4 T cell mediated influenza immunity in mice. Comprehensive assay systems are established to target CD4 and CD8 T cells, and B cells responding to influenza virus, viral hemagglutinin, or influenza vaccines.
Andrea J. Sant, Ph.D.
Professor of Microbiology and Immunology
David H Smith Center for Vaccine Biology and Immunology
Immunodominance of CD4 T cell responses to influenza virus
Dr. Sant received her Ph.D. in Immunogenetics from Washington University in St. Louis in 1985. She currently Professor of Microbiology and Immunology at the University of Rochester. The research in Dr. Sant’s laboratory centers around the molecular events that regulate MHC class II- restricted antigen presentation of influenza proteins by antigen presenting cells (APC) and CD4 T cell recruitment in vivo. Dr. Sant will lead project 3, focused on the CD4 response to infection and vaccination, and the potential impact of CD4 peptide specificity on the development of B cell responses specifically to the HA protein.
Patrick C. Wilson, Ph.D.
Dr. Wilson received his Ph.D. in Immunology from the University of Texas Southwestern Medical Center in 2000, and post- doctoral training in the Nussenzweig lab at The Rockefeller University in New York City. He currently serves as Associate Professor with tenure in the Department of Medicine/Rheumatology,at the University of Chicago.
Dr. Wilson’s interests include the development of technology to clone recombinant monoclonal antibodies from discreet populations of B cells. Dr. Wilson will lead Project 2 focused on the B cell response to infection, as well as providing monoclonal antibodies he has, and cloning additional human antibodies specific for influenza HA and NA glycoproteins.
Hana Golding, Ph.D.
Dr. Golding will assist with studies conducted under project 1. Dr. Golding received her Ph.D. in Immunology from Oregon Health Sciences University in 1981, and completed post-graduate work as a Visiting Fellow under Dr. Alfred Singer in 1985 at the Immunology Branch, NCI, NIH, and then as a Visiting Associate in the same branch under Dr. Dinah Singer in 1987. She joined the Food and Drug Administration in 1989, and since 1993 she has served as Chief of the Laboratory of Retrovirus Research in the Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). She will lead the experiments in Aims 1 and 2 of Project 1 to perform Gene Fragment Phage Display Library (GFPDL) studies of antibody specificity, a technique that she pioneered for use in influenza.
Surender Khurana, Ph.D.
Dr. Surender Khurana will assist in the conduct of studies in project 1. Dr. Khurana received his Ph.D. in Biochemistry in 2002 from Delhi University, India. He has been at the Food and Drug Administration since 2002, where he currently serves as Staff Scientist in the Division of Viral Products, Center for Biologics Evaluation and Research (CBEM). His research interests are focused on developing new molecular tools for better understanding of how different vaccine modalities and novel adjuvants improve protective immunity against influenza. Dr. Khurana developed the Surface Plasmon Resonance (SPR) assays which will be used in project 1.
Gary R. Whittaker, Ph.D.
Dr. Whittaker received his Ph.D. in Microbiology from the University of Leeds in 1991, and completed a postdoctoral fellowship in Cell Biology at Yale University. He is currently Professor in the Department of Microbiology and Immunology at Cornell University. His research interests include the cell biological and biochemical aspects of virus entry, and how virus entry pathways relate to viral pathogenesis. will assist with sequencing of the influenza virus genomes from the surveillance studies, and help interpret data in the context of HA antigenicity. He will direct experiments to assess the potential impact of bacterial coinfection on the evolution of the influenza HA cleavage site.
Luis Martínez-Sobrido, Ph.D.
Dr. Martínez-Sobrido received his Ph.D. in Virology and Molecular Biology in 2000 from the Instituto de Salud Carlos III and completed Postdoctoral training at Mount Sinai School of Medicine. He is currently Assistant Professor. He is interested in the use of plasmid-based reverse genetics techniques to rescue recombinant influenza viruses. He will construct recombinant single cycle influenza viruses for assessment of immunity.
Mark Y. Sangster, Ph.D.
Research Associate Professor
David H Smith Center for Vaccine Biology and Immunology
Dr. Sangster received his Ph.D. in Virology/Genetics from the University of Western Australia in 1991. He then completed postdoctoral work in Immunology at St. Jude’s Children’s Research Hospital. Dr. Sangster is an expert in the analysis of B cell responses to infection and vaccination. His major interests have been mucosal aspects of B cell responses in the respiratory tract and the nature of virus-specific B cell memory. He will perform studies of mucosal antibody and B cell responses, and B cell memory.
Jeanne Holden-Wiltse, M.P.H.
Ms. Holden-Wiltse received her MPH from University of Michigan School of Public Health in 1991, and has over 17 years of experience in biostatistical support having held positions in industry, government, not-for-profit organizations and academia. Ms. Holden-Wiltse will act as Co-Leader of the Data Management, Bioinformatics and Biostatistics Core.
Arnold Monto, M.D.
Arnold S. Monto, MD is the Thomas Francis Jr. Collegiate Professor of Public Health at the Department of Epidemiology, University of Michigan School of Public Health. Respiratory infections in tropical and temperate regions have been a major interest. He led the studies of respiratory illnesses in Tecumseh, MI, a landmark investigation of infection in the community Dr. Monto had been involved in assessing the efficacy of various influenza vaccines and of neuraminidase inhibitors and other compounds in prophylaxis and therapy of influenza. He now heads observational studies of effectiveness of influenza vaccines and household studies of respiratory viral infections, including respiratory syncytial virus (RSV). He has been a member of the National Allergy and Infectious Disease Advisory Council of the US National Institutes of Health and is now a member of the FDA’s Vaccines and Related Biologicals Advisory Committee (VRBPAC). He is a past president of the American Epidemiological Society, the 2009 recipient of the Alexander Fleming Award of the Infectious Diseases Society of America for lifetime achievement and the 2012 recipient of the Charles Merieux award of the National Foundation for Infectious Diseases.
Joshua Petrie, Ph. D.
Joshua G. Petrie is a Research Investigator in the Department of Epidemiology at the University of Michigan School of Public Health. He received his BS (2004) in Biology from the University of Michigan, and his MPH (2008) and PhD (2016) in Epidemiology from the University of Michigan School of Public Health. Dr. Petrie’s research interests include the epidemiology and transmission of respiratory viruses, influenza vaccine effectiveness, and serologic correlates of protection.
Scott Hensley, Ph. D.
Scott E. Hensley is an Associate Professor at the University of Pennsylvania. He received his B.A. in Biology from the University of Delaware in 2000 and his Ph.D. in Cell and Molecular Biology from the University of Pennsylvania in 2006. He completed a postdoctoral fellowship at the National Institute of Health from 2007-2010 and was an Assistant Professor at the Wistar Institute from 2010-2016. The Hensley laboratory studies mechanisms that promote antigenic drift of influenza viruses and factors that influence influenza vaccine responsiveness.
Sarah Cobey, Ph. D.
Assistant Professor in Ecology & Evolution and the Committee on Microbiology
University of Chicago
Dr. Cobey computationally models the evolution of influenza and the evolution of antibody repertoires. She uses diverse approaches that range from phylogenetics and population genetics to longitudinal and population-level dynamical models. She is working with Scott Hensley to use cross-sectional data on antibody repertoires to improve forecasting of influenza for vaccine strain selection. Her other work investigates immunodominance and original antigenic sin. Dr. Cobey received a PhD in Ecology & Evolution from the University of Michigan in 2009 and completed a postdoctoral fellowship at the Harvard School of Public Health.
Doreen M. Francis, R.N., C.C.R.C
Ms. Francis received her R.N. in 1973 from the Highland Hospital School of Nursing. She currently serves as Research Administrator and Coordinator for the Vaccine Research Unit in the Infectious Diseases Division at the University of Rochester. Ms. Francis is a highly experienced clinical research coordinator, and she will oversee regulatory and operational aspects of clinical research conducted by NYICE.
Donna Neu, PMP
Ms. Neu received her B.A. in Computer Science from the State University of New York at Oswego in 1986, and her PMP from the Project Management Institute in 2005. She is currently Project Manager of the New York Influenza Center of Excellence, and the Respiratory Pathogens Research Center at UR. As Project Manager, Ms. Neu will oversee day to day operations of NYICE and coordinate interactions between other CEIRS centers, NYICE and contract operations.
Ms Budd graduated from SUNY Brockport in 2014 with bachelors degrees in healthcare administration and psychology. She is currently Project Manager Assistant of the New York Influenza Center of Excellence, and the Respiratory Pathogens Research Center at UR. As Assistant Project Manager, Ms Budd assists in overseeing day to day operations of the RPRC and NYICE as well as putting together reports and meeting minutes to send to the National Institute of Health regarding the NYICE and RPRC contracts.